Amsterdam and cannabis go way back. In fact, cannabis culture took root in the city before it spread throughout the rest of the Netherlands. Even before prohibition, Amsterdam was home to the dedicated and passionate pioneers that would propel our history forward.

A lot has changed since then regarding cannabis policy throughout Amsterdam and the Netherlands as a whole.

Today, we want to spotlight important points in Amsterdam's cannabis history that helped put the city on the map. Nowadays, people are familiar with the city as a laidback, free-willed, cannabis-friendly oasis (especially for tourists). Let's go back in time to see how Amsterdam and cannabis' stories weave together.

1913: Cannabis is Criminalized

You likely already know about the Netherlands' cannabis criminalization in 1913. This was happening across many other parts of the world around the same time, too. International drug regulation was in its infancy.

It wasn't until the 1960s that citizens began a movement tied to cannabis and other rights. This movement was the start of the liberal, free-thinking city of Amsterdam that we have today. Prior to this point in time, though, the Opium Law lumped cannabis right in with hard drugs like cocaine and heroin.

The 1960s: Cannabis Culture Movement

The hippie culture movement running frenzied in the United States made it over to the Netherlands around the same time. Specifically, the hippie movement hit Amsterdam. With it, the number of drug-related violations in the nation started escalating.

(For reference, there were only 10 to 25 cases annually up until 1966. In 1966, that number had jumped to 74. That number drastically increased again to 544 for 1969. You get the idea.)

Provo, a small hippie movement in 1965, provoked authorities by organizing activities like manifestations and smoking sessions. Cannabis was smoked out in the open. This eventually evolved into the cultural phenomenon that it is today.

With such a record high of drug-related violations for the country, the government was forced to make a decision. At first, Dutch police persecuted any and all cannabis users. Then, though, restrictions began to loosen.

Heroin addiction had increased throughout the nation, so focusing on harder drugs' eradication compared to cannabis became a priority. The implementation of drug legislation was finally underway for drugs like cannabis, albeit with specific guidelines.

1970s: Cannabis Restrictions Loosen

June 1970 is when 1969's drug legislation implementation guidelines first took place. There was a Dutch pop festival being held in Rotterdam. Authorities merely observed the crowd rather than arrest cannabis users among the crowd.

Police officers got to witness drug use for the first time without the need to report it or arrest someone. The atmosphere was so pleasant and inviting, many were caught up in the vibe. It was quickly discovered soon after just how friendly and accommodating pot smokers are.

After this point, authorities were no longer able to justify incriminating such an innocent plant. It was soon after that lawyers and politicians alike began standing up for decriminalization and even legalization.

However, restrictive state laws remained in place. The need for a new cultural model was created, and thus, coffeeshops were born. In 1972, the first coffeeshop opened its doors. Known as a teashop back then was the very first coffeeshop, Mellow Yellow.

It only took three years for another two coffeeshops to be founded in Amsterdam. The 1970s was a beautiful start to the blossoming of coffeeshops across the country. Finally, in 1976, the Opium Law was revised. The law distinguished between cannabis products and “substances with a big risk for the individual's health.”

1992: New Coffeeshop Criteria

The number of coffeeshops in the Netherlands had peaked by the 1980s, paving the way for changes in the ‘90s. Coffeeshop-specific regulations were developed in 1991 and adopted officially in 1994.

New criteria arose in 1992 amidst this. BHOJG criteria strictly monitored and observed coffeeshops across the country.

If a shop were to commit a violation, it was closed immediately. Violations might include stocking or selling large quantities, allowing people under 18 years of age to enter, advertising cannabis, and more.

2003: Medical Cannabis Access

Cannabis policy had become more strict by 2003. However, the pharmacy began allowing users to get medicinal cannabis. Essentially, you must have a medical card, prescribed only by a doctor. With this card, you gain access to legal, medicinal cannabis. 

Fun fact: there's only one company in the Netherlands that can legally grow and supply cannabis to pharmacies. It's the only company commissioned by the Ministry of Health, Welfare and Sports to do so.

2006: “No Smoking” Attempt

Notice that we say attempt. The “no smoking” signs implemented throughout Amsterdam eventually became something of a collector's item. Certain squares or entire streets weren't allowed to be smoked on. Smoking anyway could result in a fine.

And while the citizens respected the no smoking rules, the signs were still stolen. To be a good sport, the city of Amsterdam responded by offering the signs for sale online. All proceeds ended up going to a worthy cause for the city.

2012: Introduction of Wietpas

Cannabis regulation was being tirelessly worked on. In another attempt, politicians introduced the Wietpas across the southern part of the Netherlands. The weed pass, or Wietpas, only lasted for a few months before it was abolished.

Regardless, it started the requirements that coffeeshop customers had to show proof of identity and residency. The rule essentially prevented tourists and foreigners from being able to buy cannabis legally within Amsterdam.

2014: Joint Regulation Manifest

By 2014, politicians wanted to see a different approach to drug regulation. The mayor of Amsterdam sought exactly this, started the Joint regulation manifest. This manifest went on to accept signatures from 60 other municipalities, even gaining support from some members of the government. Unfortunately, the manifest didn't make much progress after this point, as it didn't gain support from the Minister of Justice. Also, in 2014 it was estimated that in the Netherlands 1 Biljon KWH of electricity was tapped for the cultivation of Cannabis. It is unknown how much of this was used in Amsterdam but you can expect a lot!

2019: Introduction of Wietproef

What used to be a pioneering country for cannabis has since been left behind. Many states in the United States now have more legal cannabis rights than the Netherlands. And while Amsterdam continues to fight for our legal right to the plant, there's still much progress to be made. In the meantime, we cherish what we do have in regard to cannabis.

The Wietproef experiment is still underway. 10 different Dutch municipalities have the chance to sell cannabis from legal growers. We're excited to see the results of such a rewarding project. Likewise, we're eager to see more milestones in history for Amsterdam and cannabis.

Stichting Mediwiet

50 Years after founding Mellow Yellow, Wernard Bruining is still very much involved in the Cannabis Scene but now with a Foundation and a website dedicated to the workings and creation of THC Oil. It's called; Stichting Mediwiet.

This kind of dedication and passion for cannabis is common in Amsterdam. In due time we will add more stories about the pioneers of this industry in Amsterdam and why it is that we produce a Unique quality of Seeds.

Schumer further explained that the pro-cannabis lawmakers plan to use the great work achieved by the state of New York on cannabis reforms as an example. They want to reopen a case for marijuana reform that could turn around the ills of the war on drugs at the federal level. According to Schumer, Americans can be satisfied with only state laws. Not to mention that the absence of a national cannabis law creates problems for many operators in the cannabis industry.

“It was the best of times, it was the worst of times” – Charles Dickens University, college, higher education, or whatever you want to call it, can be an extremely stressful time. However, it can also be the best time of your life. It’s the first time many kids are finally free from parental or […]

The post Ketamine at University: A True Story appeared first on CBD Testers.

When cannabis markets started opening, one of the more consistent factors in legislation was the advent of very large taxes, and in many forms. From excise taxes to local taxes to sales taxes to THC taxes, states with legal policies are going crazy to bring in as much tax money as possible, no matter how […]

The post Massachusetts Rakes It In With Cannabis Taxes, More Than Alcohol appeared first on CBD Testers.

One thing that is sorely lacking from California’s cannabis industry is consistency. Starting with statewide pot shortages just a couple of years ago, to a $100 million bailout last year, and now insane levels of overproduction that are driving market prices into the dirt – it seems that California keeps overcorrecting at every turn, and […]

The post California is Drowning in Cannabis, Product Prices Plummet   appeared first on CBD Testers.

HONG KONG, Feb 17, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 11 February 2022 (EST local time), an Investigational New Drug application ("IND"), for the Company's First-in-Class (FIC) asthma therapeutic product SM17 (Humanized anti-IL17RB monoclonal antibody for injection) has been submitted and accepted by the U.S. Food and Drug Administration ("FDA"). The Company plans to initiate the First-In-Human study in the U.S. in first quarter of 2022, once IND is approved by FDA.
SM17 is the world's first monoclonal antibodies targeting IL17BR co-developed by SinoMab and LifeArc (a medical research charity based in the United Kingdom). SM17 has a wide range of indications, including indications with large market volumes such as asthma and diseases with high mortality rates such as idiopathic pulmonary fibrosis. Comparing to other products on the market, SM17 enjoys differentiation advantages. With the preclinical data and unique mechanism of action of SM17, Company believes that SM17 potentially has a broader and more beneficial effect on asthma treatment than other approved biologics.

In the global market, the number of asthma patients is gradually increasing and is expected to reach 247.5 million by 2023 and further increase to 267.7 million by 2030. The number of asthma patients in the PRC is increasing at a greater pace than the global rate and is forecasted to reach 25.6 million by 2023 and further increase to 27.8 million by 2030. In terms of market size, the global asthma market is projected to reach US$25.1 billion by 2023 and US$34.6 billion by 2030. However, the asthma market in the PRC is expected to reach RMB36.4 billion by 2023 and RMB65.0 billion by 2030. In terms of treatment options, traditional asthma treatment is based on inhaled corticosteroid, but they are prone to serious adverse effects, especially in adolescents. Drug resistance can also develop if used for a long time. The introduction of SM17 is expected to provide a better treatment option in terms of the balance of efficacy and safety.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "following the acceptance of the IND application for SN1011 for the treatment of multiple sclerosis by the NMPA, the acceptance of the SM17 IND application by the FDA fully demonstrates the efficient execution of the Company's new drug R&D program. There is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. We are therefore confident in the enormous prospects of SM17's clinical development. Our core products, including SM03, SN1011 and SM17, is making progress on the clinical R&D smoothly, driving the Company moving steadily towards commercialization. In the future, we will accelerate our projects implementation to bring benefits to patients and create value for shareholders through innovation."

About SM17
SM17 is known to be the world's first humanized, IgG4-k monoclonal antibody for new drug development, which targets IL-17RB. And IL-17RB is a type-I single transmembrane glycoprotein belonging to IL-17 receptor family. The binding of SM17 to IL-17RB could suppress Th2 immune responses induced by a category of cytokines called "alarmin", which has shown to be implicated in the pathogenesis of allergic disease and airway viral responses. Alternative approach targeting upstream mediators of the Th2 inflammatory cascade, such as "alarmins", is expected to have a broader effect on airway inflammation and to provide more effective asthma control than currently available therapies, and products with similar mechanism of action as SM17 have been approved by FDA.

About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases

Unfortunately, the War on Drugs has made it difficult for African Americans to succeed in the cannabis industry. It’s also harder on Black Americans, who are 4 times more likely to be arrested for marijuana-related charges compared to white people. For them, getting a slice of the cannabis pie is much more challenging. Because of that, and because it’s Black History Month, here are some of the most notable African American pioneers in cannabis that deserve recognition for their achievements in the challenging industry. Let’s allow them to inspire the next generation of African-American cannabis trailblazers:

Who knew that the coronavirus was going to end up causing the cancellation of so many events. Remember when people were talking about it at the end of 2019? Many people believed it would be out of our hair in a few months. Well, essentially three years later, here we are. It’s 2022 and covid […]

The post European Cannabis Events of 2022: Are They Happening? appeared first on CBD Testers.

A senior British commander in the Metropolitan police imbibed substances while on holiday in France, and people are talking.

The post British Police Commander Accused of Taking Drugs While on Vacation appeared first on High Times.

As eating habits and sedentary lifestyles make us balloon out as a general population, for some, it’s about losing weight, and for some its about gaining it. New research into psychedelics show they can be an effective treatment for eating disorders like anorexia and bulimia, where self-image and control can play a big role in […]

The post How Psychedelics Can Positively Impact Eating Disorders and Self Image appeared first on CBD Testers.

Perhaps, it’s time to accept that, “We the People” like to get a bit crunked-up every now and then and that it’s completely okay. It’s much more effective to control the drugs than it is to prohibit them, and if you tax recreational drug use like any other recreational substance – the problem would essentially fund the only solution that would have ever worked – education, harm reduction, supply chain management, purity controls.

Studies at Rensselaer Polytechnic and other reputable institutions point out that hemp could be a perfect replacement for steel. These scientists claim these plants are phenomenal crops meant to be mass-cultivated on industrial scales to produce dozens of products. For example, the various car parts produced from steel or plastic can be alternatively made from hemp. And hemp is a much stronger and more durable raw material than steel and plastic. Yes, hemp is stronger than both materials and products derived from the crop that have long-lasting lifespans.